Gene Therapy Investment At All Time High, Commercialization Challenges Noted
Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.
You may also be interested in...
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.